American Society of Hirudotherapy

Destructive Mold Osteomyelitis of the Wrist Caused by Scedosporium apiospermum-A Case Report

Case report published in Journal of Clinical Medicine (2026)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportClinical LiteratureSafety & Infection ControlBo C et al. · Journal of clinical medicine, 2026

Abstract

Background: Wrist osteomyelitis caused by Scedosporium apiospermum is exceedingly rare. Its indolent course and destructive potential may result in extensive bone loss and pose substantial diagnostic and therapeutic challenges. Methods: We report a case of chronic wrist osteomyelitis caused by Scedosporium apiospermum in a 68-year-old kidney-pancreas transplant recipient. Results: Following diagnosis, systemic antifungal therapy with voriconazole was initiated, and multiple surgical debridements were performed to achieve local disease control, resulting in a large defect of the carpus and distal forearm. Hand salvage was attempted using an osteocutaneous triple-barrel fibula flap. The postoperative course was complicated by congestion of the fibula skin island, which was managed with leech therapy. Subsequent infection with a multi-resistant Aeromonas spp. and Morganella morganii led to flap necrosis, ultimately requiring transradial forearm amputation. Conclusions: Destructive Scedosporium apiospermum osteomyelitis in immunocompromised patients is a major challenge for reconstructive surgeons. Interdisciplinary management is essential as mold eradication is only achievable through a combined surgical and antimicrobial approach. In advanced destructive osteomyelitis, the choice between limb salvage and amputation should be individualized, considering patient comorbidities, reconstructive risk, and patients' preferences. This case highlights the importance of balancing careful indication and patient counseling in complex clinical scenarios.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Summary

Case of chronic Scedosporium apiospermum wrist osteomyelitis in a 68-year-old kidney-pancreas transplant recipient; leech-treated congestion of the fibula flap skin island was followed by multiresistant Aeromonas and Morganella infection, flap necrosis, and transradial amputation.

Why This Matters for Hirudotherapy

This case report describes chronic wrist osteomyelitis caused by Scedosporium apiospermum in a 68-year-old kidney-pancreas transplant recipient, managed with voriconazole and multiple surgical debridements followed by an osteocutaneous triple-barrel fibula flap. The postoperative course was complicated by congestion of the fibula skin island managed with leech therapy; however, subsequent infection with multi-resistant Aeromonas spp. and Morganella morganii led to flap necrosis and transradial amputation. This case illustrates both the application and a serious risk of leech therapy — Aeromonas infection — in a highly immunocompromised patient. This is a single case report in a complex immunosuppressed patient; the abstract does not detail the leech therapy protocol or establish definitive causation between leech use and the subsequent infection.

Citation

Reference (Vancouver style)

Bo C, Conen A, Giacalone M, Marti R, Grobholz R, Seeger H, et al. Destructive Mold Osteomyelitis of the Wrist Caused by Scedosporium apiospermum-A Case Report. J Clin Med. 2026;15(8):3035. doi:10.3390/jcm15083035. PMID: 42074834

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.